Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.43
-0.0289-0.09%
Post-market: 32.450.0189+0.06%19:30 EDT
Volume:4K
Turnover:120.89K
Market Cap:41.35M
PE:- -
High:32.54
Open:32.54
Low:32.29
Close:32.46
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:1.09
T/O Rate:0.29%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Weight-Loss Drug Giant Sheds 13,000 Positions

Deep News
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

GlobeNewswire
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Ultragenyx price target raised to $35 from $32 at Barclays

TIPRANKS
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Health Advisory: Avoid Misusing Weight-Loss Medications, Prioritize Evaluation Before Treatment

Deep News
·
Sep 19

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19

Eli Lilly - Inluriyo with Verzenio NOW Available in the United States

THOMSON REUTERS
·
Sep 19